Innovation for the oral treatment of mucosal cancers

Highlights

Innovation for the oral treatment of mucosal cancers

Our mission

Develop a safe and efficient therapeutic platform based on oral monoclonal IgA antibodies

Our focus

  • ABC-101, a unique, orally-active IgA anti-CEA developped for the treatment of mucosal cancers
  • ABC-201, an IgA monoclonal antibody currently under development in Endometriosis

Our goals

  • IND for ABC-101 in 2026 and a clinical POC in several mucosal cancers in 2027
  • IND for ABC-201 in 2027 for the treatment of Endometriosis

The most deadly cancers
are mucosal

New cases/year

5-Y survival

Global incidence: new cases/year 5 years survival rate (Source IARC 2020)

IgA as a valuable alternative to IgG

  • Its polymeric and T-shape
    gives IgA a higher avidity
    for its target than IgG
  • IgA recruits neutrophils, ten
    times more efficiently
    than
    NK cells recruited by IgG
  • IgA glycosylations are less
    critical for cell cytotoxicity

    induction than for IgG
  • Its polymeric and T-shape gives
    IgA a higher avidity
    for its target than IgG
  • IgA recruits neutrophils, ten
    times more efficiently
    than
    NK cells recruited by IgG
  • IgA glycosylations are less
    critical for cell cytotoxicity

    induction than for IgG

IgA is a unique antibody suitable for Oral immunotherapy
as an alternative to exclusively IV/SC IgG administration

A unique technological platform

IgA is extremely difficult to sort from standard hybridoma techniques (1% IgA vs 40% IgM, 60% IgG) and has thus being up to now under estimated by Pharma at the benefit of IgG approaches.

Abcely has developped a unique platform for the Identification, Lead Optimisation, Manufacturing, Analysis and in vitro/vivo testing of slgA

ABC-101
The first slgA
anti-CEA drug

Secretory IgA (sIgA) is extremely resistant to enzymatic attacks and high pH variations (from acidic to basic)

Secretory IgA is actively absorbed without degradation by receptors expressed on M cells, mostly located in Peyer Patches in human ileum

Carcinoembryonic antigen (CEA), present at the apical membrane of cells in normal tissues, is one of the most widely used tumor marker for monitoring tumor recurrence after surgical resection and prognosis. CEA overexpression is associated to many types of cancers (up to 98% of colorectal cancers) IgA is the only relevant Ig to target CEA because IgG binds to the plasma CEA and does not reach the tumor efficiently

In vivo efficacy of ABC-101 in an advanced metastatic CRC model After 3 weeks of oral treatment, ABC-101 was well tolerated As a first-line monotherapy, ABC-101 signicantly reduced tumor size when given orally and showed a higher therapeutic benefit than the clinical IgG SOC (Erbitux®) given in IV In combination with Irinotecan, ABC-101 given orally showed a stronger therapeutic benefit on tumor growth than the IV Gold standard IgG, Erbitux®

In vivo efficacy
of ABC-101 in
an advanced
metastatic CRC

In vivo efficacy of ABC-101 in an advanced metastatic CRC model.

  • After 3 weeks of oral treatment, ABC-101 was well tolerated .
  • As a first-line monotherapy, ABC-101 signicantly reduces tumor size when given orally and shows a higher therapeutic benefit than the clinical SOC (Erbitux®) given IV.
  • In combination with Irinotecan, ABC-101 given orally shows a stronger therapeutic benefit on tumor growth than the Gold standard Erbitux® IV

ABC-201,
a promissing treatment addressing a high unmet need disease: Endometriosis

Development plan – Key steps

Leadership Team

Jean-Marc Herbert, PhD
Founder and CEO
Former SVP Discovery at Sanofi +40Y of drug discovery and dev. Investor and multi-entrepreneur

Olivier Favre-Bulle,PhD
CTO
 

François Desmarest
CFO

Armelle Cuvillier, PhD
CSO
Former CSO of B Cell Design Immunologist

Béatrice Lejeune
Chief Regulatory Officer

Mylène Brousse
Research Engineer

Our partners

Scientific Advisory Board

Pr. S. Paul, PhD
CHU, Saint-Etienne, FR
Professor / Practitioner
Immunology & Vaccinology

Pr. M. Van Egmond, PhD
UMC, Amsterdam, NL
Professor in Oncology and inflammation

Pr. M. Ducreux, MD
IGR, Paris FR
Former chair of the EORTC
Co-Chair of the ESMO Gastrointestinal cancers Congress 2024


Strategic Board

Leila Nicolas, PhD
Partner at Go Capital

Gabriel Festoc
Former CEO at Polyplus

Stéphane Loze, PhD
Former head of strategy and oncology therapeutic units at Roche


Marc Bonneville, PhD
Co-founder of Innate Pharma

Contact us